PRANA'S PBT2 COMPLETES INITIAL PHASE I TRIAL PROGRAM

Prana Biotechnology has announced the successful completion of a second Phase I trial with its lead compound, PBT2, under development as a therapy for Alzheimer's disease.

The Phase I, multidose, double blind, placebo-controlled, dose escalation study, was conducted in Utrecht, the Netherlands, on 32 healthy male and female volunteers between the ages of 45 and 75. The study was designed to evaluate the safety, tolerability and pharmacokinetics of multiple doses of PBT2 administered once daily for seven days. Initial results indicate that multiple doses of PBT2 are generally well tolerated by both male and female subjects in the critical target age group for Alzheimer's disease treatment.